Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 7/20 | 0.54 |
| ▸ | MET | P08581 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16966150 | 0.87 | INSR (0.71) | INSRMETEGFRALKAXL | |
| SCHEMBL2062228 | 0.86 | ALK (0.58) | INSRMETEGFRALKFLT3 | |
| SCHEMBL16966032 | 0.84 | INSR (0.53) | INSRMETEGFRALKAXL | |
| SCHEMBL886071 | 0.84 | MET (0.76) | INSRMETEGFRALK | |
| SCHEMBL16966003 | 0.83 | MET (0.46) | INSRMETEGFRALKAXL | |
| SCHEMBL16966020 | 0.79 | CCNA2 (0.49) | INSRMETEGFRALKAXL | |
| SCHEMBL16965993 | 0.79 | ALK (0.64) | INSRMETALK | |
| SCHEMBL16966205 | 0.79 | MET (0.47) | INSRMETEGFRALKAXL | |
| SCHEMBL886819 | 0.78 | MET (0.76) | INSRMETEGFRALK | |
| SCHEMBL30833783 | 0.77 | SYK (0.47) | METEGFRALKAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | claimed |